ProFound Therapeutics, a company pioneering the expanded human proteome to develop groundbreaking medicines for various diseases, has announced a four-year collaboration with Novartis. This collaboration aims to discover and develop novel therapeutics for cardiovascular disease using Novartis’ ProFoundry Platform. Under the four-year collaboration agreement, ProFound will receive $25 million in upfront and near-term milestone payments with the potential transaction value from downstream miles...